Author
Cui Tang
Bio: Cui Tang is an academic researcher from Fudan University. The author has contributed to research in topics: Drug carrier & Chitosan. The author has an hindex of 35, co-authored 57 publications receiving 4944 citations.
Topics: Drug carrier, Chitosan, Nanocarriers, Mucoadhesion, Medicine
Papers published on a yearly basis
Papers
More filters
TL;DR: In vivo biodistribution suggested that NPs with slight negative charges and particle size of 150 nm were tended to accumulate in tumor more efficiently, and could serve as a guideline in the rational design of drug nanocarriers with maximized therapeutic efficacy and predictable in vivo properties.
2,069 citations
TL;DR: Self-assembled nanoparticles between TMC-Cys and protein drugs could be an effective and safe oral delivery system and biocompatibility assessment revealed lack of toxicity of TMC -Cys NP.
407 citations
TL;DR: Due to the cross-linked O-CMC network, in vitro muco-adhesive force and mechanical properties, including compression and tensile modulus, of the SPH-IPN were greatly improved when compared with the CSPH.
266 citations
TL;DR: Rhodamine B labeled carboxylated chitosan grafted nanoparticles with different particle sizes and similar Zeta potentials provided guidelines for the rational design of oral nanocarriers for protein drugs in terms of particle size.
181 citations
TL;DR: Multi-layered nanocomplexes were designed here to provide smart co-delivery of doxorubicin (DOX) and vascular endothelial growth factor (VEGF) siRNA and served as an effective and safe vector to maximize synergistic effect of chemodrugs and therapeutic genes.
155 citations
Cited by
More filters
TL;DR: Findings suggest that, at least in part, the encountered beneficial effects of essential oils are due to prooxidant effects on the cellular level.
6,174 citations
TL;DR: This Perspective explores and explains the fundamental dogma of nanoparticle delivery to tumours and answers two central questions: ‘ how many nanoparticles accumulate in a tumour?’ and ‘how does this number affect the clinical translation of nanomedicines?'
Abstract: This Perspective explores and explains the fundamental dogma of nanoparticle delivery to tumours and answers two central questions: ‘how many nanoparticles accumulate in a tumour?’ and ‘how does this number affect the clinical translation of nanomedicines?’
3,335 citations
TL;DR: Recent progress in overcoming challenges with regards to effectively delivering hydrogels inside the body without implantation, prolonging the release kinetics of drugs fromhydrogels, and expanding the nature of drugs which can be delivered using hydrogel-based approaches is discussed.
3,140 citations
TL;DR: The fundamental concepts of enhanced permeability and retention effect (EPR) are revisited and the mechanisms proposed to enhance preferential "retention" in the tumor, whether using active targeting of nanoparticles, binding of drugs to their tumoral targets or the presence of tumor associated macrophages are explored.
2,199 citations